Sept. 23, 2024 -- Samsung Bioepis Co., Ltd. today presented the “totality-of-the-evidence” supporting extrapolation of atypical hemolytic uremic syndrome (aHUS) indication on EPYSQLI™ (SB12), a biosimilar to Soliris1 (eculizumab), at the 56th European Society for Paediatric Nephrology (ESPN 2024). The congress will be taking place from September 24 to 27, 2024 in Valencia, Spain.
SB12, a biosimilar to reference eculizumab (ECU-RP), was approved by the European Commission (EC) in May 2023 for t